Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Lloyd-Smith Malcolm</u>						1									Director			10% Ow	ner	
				- []	J								X	Officer below)	(give title		Other (s below)	pecify		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)									Chief Regulatory Officer					
12780 EL CAMINO REAL						02/05/2020														
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
SAN DIEGO CA 92130													X	Form filed by One Reporting Person						
(City) (State) (Zip)				-										Form filed by More than One Reporting Person						
(City)	(σιαιε) (Διμ)																			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					.	2A. Deemed Execution Date, ar) if any (Month/Day/Yea			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			i 5)	5. Amount of Securities Beneficially Owned Following		Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership	
						(WOTE	iiDayi reai j		0)			(4)			Reporte	d [(1) (111		(Instr. 4)	
									Code		Amount	(A) or (D)	Price		Transac (Instr. 3					
Common Stock 02/05/20					020	0			S ⁽¹⁾		1,083	D	\$103.	03.0345(2)),455		D		
Common Stock 02/				02/05/20	:020				S ⁽³⁾		865	D	\$103.	3.0595 ⁽⁴⁾ 2		1,127		D		
Common Stock 02/06/202				020	0			S ⁽⁵⁾		1,490	D	\$101.	101.5154 ⁽⁶⁾		2,287		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
		1	1		-	calls	1		_								_			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
													or	ount						
									Date		Expiration		Nur of	nber						
					Code	٧	(A)	(D)		cisable		Title	Sha	res						
Stock Option	\$102.9	02/06/2020			A		38,342			(7)	02/06/2030	Commo		342	\$0.00	38,342		D		
Restricted	(8)	02/06/2020			Α		6,074			(9)	(9)	Comm	on 6.0	074	\$0.00	6,074		D		

Explanation of Responses:

- 1. Sale of 1,083 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (842) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 1005-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$101.90 to \$105.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. Sale of 865 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (672) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$101.90 to \$105.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 5. Sale of 1,490 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,160) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 6. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$100.12 to \$103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 7. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- 8. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- 9. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024.

Remarks:

/s/ Darin Lippoldt, Attorney-in-Fact

** Signature of Reporting Person

02/07/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.